0000899243-23-007110.txt : 20230306
0000899243-23-007110.hdr.sgml : 20230306
20230306061510
ACCESSION NUMBER: 0000899243-23-007110
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230303
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sumitomo Pharma Co., Ltd.
CENTRAL INDEX KEY: 0001446601
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 23707473
BUSINESS ADDRESS:
STREET 1: 6-8 DOSHOMACHI 2-CHOME
STREET 2: CHUO-KU
CITY: OSAKA
STATE: M0
ZIP: 541-0045
BUSINESS PHONE: 816-6203-5321
MAIL ADDRESS:
STREET 1: 6-8 DOSHOMACHI 2-CHOME
STREET 2: CHUO-KU
CITY: OSAKA
STATE: M0
ZIP: 541-0045
FORMER NAME:
FORMER CONFORMED NAME: Dainippon Sumitomo Pharma Co Ltd
DATE OF NAME CHANGE: 20080930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sumitomo Chemical Co., Ltd.
CENTRAL INDEX KEY: 0001798550
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 23707474
BUSINESS ADDRESS:
STREET 1: 7-1, NIHONBASHI 2-CHOME
STREET 2: CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-6020
BUSINESS PHONE: 813-5201-0222
MAIL ADDRESS:
STREET 1: 7-1, NIHONBASHI 2-CHOME
STREET 2: CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-6020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sumitovant Biopharma Ltd.
CENTRAL INDEX KEY: 0001798244
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 23707472
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: (646) 802-3660
MAIL ADDRESS:
STREET 1: C/O ROIVANT SCIENCES, INC.
STREET 2: 320 WEST 37TH STREET, 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Myovant Sciences Ltd.
CENTRAL INDEX KEY: 0001679082
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: CA
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 207-400-3351
MAIL ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-03
0
0001679082
Myovant Sciences Ltd.
MYOV
0001798550
Sumitomo Chemical Co., Ltd.
7-1 NIHONBASHI 2-CHOME
CHUO-KU, TOKYO
M0
103-6020
JAPAN
0
0
1
0
0001446601
Sumitomo Pharma Co., Ltd.
6-8 DOSHOMACHI 2-CHOME
CHUO-KU, OSAKA
M0
541-0045
JAPAN
0
0
1
0
0001798244
Sumitovant Biopharma Ltd.
7TH FLOOR 50 BROADWAY
LONDON
X0
SW1H 0DB
UNITED KINGDOM
0
0
1
0
Common Shares
2023-03-03
4
J
0
4243005
0.00
D
45798176
I
See Footnote
Option (Right to Acquire)
27.00
2023-03-03
4
J
0
1
0.00
A
2023-03-03
2023-03-30
Common Shares
4243005
1
I
See Footnote
On March 3, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") voluntarily returned to Roivant Sciences Ltd., a Bermuda exempted company limited by shares ("Roivant"), for no consideration, 4,243,005 common shares, par value $0.000017727 per share (each, a "Common Share") of Myovant Sciences Ltd. (the "Issuer") subject to that certain Share Return Agreement, dated as of December 27, 2019, by and among Sumitovant, Roivant and Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma") (the "Share Return"). In addition, Sumitovant, Sumitomo Pharma and Roivant agreed that, in the event that the Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the "Merger Agreement"), by and among the Issuer, Sumitovant, Zeus Sciences Ltd. and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma, is terminated in accordance with its terms, Roivant will return such Common Shares to Sumitovant.
Sumitovant directly owns 45,798,176 Common Shares following the Share Return. Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma, which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the "Option") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023.
Sumitomo Chemical Co., Ltd., By: /s/ Takeo Kitayama, Executive Officer, General Manager, Corporate Planning Office
2023-03-06
Sumitomo Pharma Co., Ltd., By: /s/ Tsutomu Nakagawa, Senior Director, Global Corporate Strategy
2023-03-06
Sumitovant Biopharma Ltd., By: /s/ Monika Adams, Transactions Officer
2023-03-06